Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 72.2%

Neg 0% Neu 0% Pos 72.2%

Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.